Several studies have focused on the effect of different lengths of linker peptides on the properties of single-chain Fv (ScFv). The expressing level and stability of anti-CD16 ScFv with common linker peptide (Gly(4)Ser)(3) were very poor. Considering 3-D structures of heavy and light chain variable region gene of anti-CD16 antibody, a novel linker peptide PT7 (i.e. Gly(3)SerAla(3)) was designed. As a comparison, the linker PT5 (Gly(4)Ser) was chosen to construct anti-CD16 ScFv. A molecular modeling of anti-CD16 ScFv antibody with the two different linker peptides was designed using computer-assisted modeling techniques and molecular dynamics method. Based on the crystal structure of human IgG1 Fc fragment-Fc gamma receptor III (Fc gamma RIII) complex, putative interactions between anti-CD16 ScFv antibody with two different linker peptide and Fc gamma receptor III fragment were predicted with Docking method. Using molecular graphic techniques, the structure-function relationship of anti-CD16 ScFv antibody with two different linker peptides was analyzed and the combining ability was predicted. The binding activity to Daudi cells by FACS showed that anti-CD16 ScFv antibody with two different linker peptides possessed similar ability and the experimental result was consistent with the theoretical prediction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jim.2003.07.001 | DOI Listing |
Mol Pharm
June 2021
Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario K1A 0R6, Canada.
Multispecific antibodies that bridge immune effector and tumor cells have shown promising preclinical and clinical efficacies. Here, we isolated and characterized novel llama single-domain antibodies (sdAbs) against CD16. One sdAb, NRC-sdAb048, bound recombinant human and cynomolgus monkey CD16 ectodomains with equivalent affinity (: 1 nM) but did not recognize murine CD16.
View Article and Find Full Text PDFLeukemia
June 2021
Division of Adult and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.
The low 5-year survival rate for patients with acute myeloid leukemia (AML), primarily caused due to disease relapse, emphasizes the need for better therapeutic strategies. Disease relapse is facilitated by leukemic stem cells (LSCs) that are resistant to standard chemotherapy and promote tumor growth. To target AML blasts and LSCs using natural killer (NK) cells, we have developed a trispecific killer engager (TriKE) molecule containing a humanized anti-CD16 heavy chain camelid single-domain antibody (sdAb) that activates NK cells, an IL-15 molecule that drives NK-cell priming, expansion and survival, and a single-chain variable fragment (scFv) against human CLEC12A (CLEC12A TriKE).
View Article and Find Full Text PDFCancers (Basel)
September 2020
Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
We improved the bispecific antibody platform that primarily engages natural killer (NK) cells to kill cancer cells through antibody-dependent cellular cytotoxicity (ADCC) by adding IL-15 as a crosslinker that expands and self-sustains the effector NK cell population. The overall goal was to target B7-H3, an established marker predominantly expressed on cancer cells and minimally expressed on normal cells, and prove that it could target cancer cells in vitro and inhibit tumor growth in vivo. The tri-specific killer engager (TriKE) was assembled by DNA shuffling and ligation using DNA encoding a camelid anti-CD16 antibody fragment, a wild-type IL-15 moiety, and an anti-B7-H3 scFv (clone 376.
View Article and Find Full Text PDFRep Biochem Mol Biol
April 2020
Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran.
Background: : Immunotherapy of cancer by bispecific antibodies (bsAb) is an attractive approach for retargeting immune effector cells including natural killer (NK) cells to the tumor if the proper expression and purification of the bsAb for such applications could be addressed. Herein, we describe expression of a recombinant bsAb (bsHN-CD16) recognizing NK-CD16 and hemagglutinin neuraminidase (HN) of Newcastle Disease Virus (NDV). This bsAb might be efficient for stimulation of NK cells via coupling to HN on the surface of the NDV-infected tumor cells.
View Article and Find Full Text PDFCancer Immunol Res
September 2020
Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Natural killer (NK) cells are potent immune modulators that can quickly lyse tumor cells and elicit inflammatory responses. These characteristics make them ideal candidates for immunotherapy. However, unlike T cells, NK cells do not possess clonotypic receptors capable of specific antigen recognition and cannot expand via activating receptor signals alone.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!